Plasma Metabonomic Profiling of Diabetic Retinopathy

• Published in: Diabetes (New York, N.Y.) Vol. 65; no. 4; pp. 1099 - 1108
• Main Authors: Chen, Liyan, Cheng, Ching-Yu, Choi, Hyungwon, Ikram, Mohammad Kamran, Sabanayagam, Charumathi, Tan, Gavin S.W., Tian, Dechao, Zhang, Liang, Venkatesan, Gopalakrishnan, Tai, E Shyong, Wang, Jie Jin, Mitchell, Paul, Cheung, Chiu Ming Gemmy, Beuerman, Roger Wilmer, Zhou, Lei, Chan, Eric Chun Yong, Wong, Tien Yin
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01.04.2016
• Subjects: Adult; Aged; Biomarkers - blood; Biomarkers - metabolism; Case-Control Studies; Chromatography; Cohort Studies; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - metabolism; Diabetic retinopathy; Diabetic Retinopathy - blood; Diabetic Retinopathy - metabolism; Female; Humans; Kidney diseases; Male; Mass spectrometry; Metabolites; Metabolome; Metabolomics; Middle Aged; Plasma; Singapore
• ISSN: 0012-1797; 1939-327X; 1939-327X
• DOI: 10.2337/db15-0661

Diabetic retinopathy (DR) is the most common microvascular complication of diabetes and the leading cause of visual impairment in working-age adults. Patients with diabetes often develop DR despite appropriate control of systemic risk factors, suggesting the involvement of other pathogenic factors. We hypothesize that the plasma metabolic signature of DR is distinct and resolvable from that of diabetes alone. A nested population-based case-control metabonomic study was first performed on 40 DR cases and 40 control subjects with diabetes using gas chromatography–mass spectrometry. Eleven metabolites were found to be correlated with DR, and the majority were robust when adjusted for metabolic risk factors and confounding kidney disease. The metabolite markers 2-deoxyribonic acid; 3,4-dihydroxybutyric acid; erythritol; gluconic acid; and ribose were validated in an independent sample set with 40 DR cases, 40 control subjects with diabetes, and 40 individuals without diabetes. DR cases and control subjects with diabetes were matched by HbA1c in the validation set. Activation of the pentose phosphate pathway was identified from the list of DR metabolite markers. The identification of novel metabolite markers for DR provides insights into potential new pathogenic pathways for this microvascular complication and holds translational value in DR risk stratification and the development of new therapeutic measures.